AB Science announced that its Phase 2/3 clinical trial evaluating masitinib, the company’s lead compound to treat amyotrophic lateral sclerosis (ALS) patients, has met its primary objective. The ongoing study is currently recruiting participants and expects to finish in June 2017. “The positive outcome of this study in ALS is a significant milestone…
Search results for:
Neuraltus Pharmaceuticals announced that it will initiate a second Phase 2 clinical trial of its investigational drug candidate NP001 for the treatment of amyotrophic lateral sclerosis (ALS), with the intent of confirming positive earlier findings in patients with elevated levels of baseline inflammation and further evaluating the drug’s efficacy. Inflammation is thought to be a…
Leaders in the field of induced pluripotent stem cell (iPSC) – a technology that can help derive motor neurons from people who suffer from amyotrophic lateral sclerosis (ALS) – have published a cutting-edge review, identifying advances and challenges in ALS modeling ability and calling for the development and adoption of rigorous criteria…
Social Clips
7 ALS Headlines
1. Herantis’ Potential ALS Treatment, CDNF, Recommended for Orphan Drug Status by EMA Herantis Pharma announced that it has received a positive opinion from the European Medicines Agency’s Committee for Orphan Medicinal Products (COMP) on…
Social Clips
ALS Awareness – Les Turner ALS Foundation
https://www.youtube.com/watch?v=emZjNcD484E In this Comcast NewsmakersIL video, learn more about the Les Turner ALS Foundation. “Since 1977, the Les Turner ALS Foundation has been Chicagoland’s leader in patient services, research, and education for Amyotrophic Lateral Sclerosis (ALS). The foundation serves nearly 90% of people living with ALS in the Chicagoland…
News
Novel Prodrug with Potential for ALS and Like Diseases Acquired by Startup, Yumanity Therapeutics
Yumanity Therapeutics has recently licensed a prodrug invented at the University of Arizona (UA), adding it to the company’s expanding platform of potential therapies for neurodegenerative diseases like amyotrophic lateral sclerosis (ALS). Neurodegenerative diseases result from errors made during the building and folding processes of proteins within the cell. In 2009, UA…
Herantis Pharma announced that it has received a positive opinion from the European Medicines Agency’s Committee for Orphan Medicinal Products (COMP) on its application for orphan drug designation for CDNF as a potential treatment for amyotrophic lateral sclerosis (ALS). A positive opinion is the first step toward orphan drug designation which, in…
The California Institute for Regenerative Medicine (CIRM)’s Independent Citizens Oversight Committee has approved a $6.3 million grant to fund a research team’s work into a new human embryonic stem cell-based therapy, involving astrocytes, to rescue and restore neurons damaged as a consequence of amyotrophic lateral sclerosis (ALS). Team members, from the University of…
Social Clips
7 ALS Headlines You Can’t Miss
1 – 7 Ways to Diagnose ALS Learn more about the different ways to diagnose ALS. Read full article: https://bit.ly/1UWLNAI 2 – ALS Gene Drives Disease Development Through Neuroinflammation, Researchers Find Mutations in the C9orf72 gene are the most common genetic cause leading to amyotrophic…
Mutations in the C9orf72 gene are the most common genetic cause leading to amyotrophic lateral sclerosis (ALS). Despite this, researchers have not been able to determine what the normal function of the gene really is. Now, scientists from Cedars-Sinai Medical Center in Los Angeles have revealed that the gene contributes to…